Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib

Background: The use of tyrosine kinase inhibitors has dramatically improved the prognosis of chronic myeloid leukemia (CML). Nilotinib has been reported to be associated with hypothyroidism and hyperthyroidism. Objectives: The current study aims to evaluate the prevalence of thyroid dysfunction in a...

Full description

Bibliographic Details
Main Authors: Khaleed J Khaleel, Ahmed H Matloob, Abdalsalam Hatim
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Iraqi Journal of Hematology
Subjects:
Chronic myeloid leukemia
nilotinib
thyroid dysfunction
tyrosine kinase inhibitor
Online Access:http://www.ijhonline.org/article.asp?issn=2072-8069;year=2018;volume=7;issue=1;spage=33;epage=38;aulast=Khaleel

Internet

http://www.ijhonline.org/article.asp?issn=2072-8069;year=2018;volume=7;issue=1;spage=33;epage=38;aulast=Khaleel

Similar Items